Increased urinary excretion of interleukin-17 in nephrotic patients

被引:29
|
作者
Matsumoto, K
Kanmatsuse, K
机构
[1] Saitama Prefectural Univ, Dept Med Technol, Coll Med Sci, Koshigaya, Saitama 3438540, Japan
[2] Nihon Univ, Sch Med, Dept Internal Med 2, Tokyo 173, Japan
关键词
minimal-change nephrotic syndrome; IgA nephropathy; nephrotic syndrome; T cells; interleukin-17;
D O I
10.1159/000058399
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim:Interleukin (IL)-17 is a newly discovered cytokine that is secreted by activated memory CD4+T cells and modulated the early stage of immune response. To elucidate the pathophysiology of minimal-change nephrotic syndrome (MCNS), we focused on IL-17, which is one of the key factors in regulating an inflammatory response, and thus determined the daily excretion of IL-17 in urine. Methods: For this purpose, excretion levels of IL-17 were measured in the urine of patients with MCNS during relapse and remission using a highly sensitive sandwich enzyme-linked immunosorbent assay. The data obtained were compared with levels of daily urinary excretion of IL-17 in patients with IgA nephropathy (IgAN). A group of healthy subjects served as control. In both experimental groups urine levels of IL-17 excretion were plotted against their daily urinary protein excretion. Results:We demonstrated increased levels of IL-17 excretion in the urine of patients with MCNS and IgAN as compared to the non-nephrotic and healthy controls. In MCNS the daily urinary IL-17 (uIL-17) excretion was increased and returned to baseline with remission of the nephrotic syndrome (NS). We also demonstrated a positive correlation between urinary protein excretion and daily uIL-17 excretion. Conclusion: Taken together, these data indicate that uIL-17 excretion is increased during the NS, suggesting the possibility that daily uIL-17 excretion may reflect the disease activity of NS. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 50 条
  • [31] Interleukin-17 gene expression in patients with rheumatoid arthritis
    Kohno, Mika
    Tsutsumi, Akito
    Matsui, Hiroto
    Sugihara, Makoto
    Suzuki, Takeshi
    Mamura, Mizuko
    Goto, Daisuke
    Matsumoto, Isao
    Ito, Satoshi
    Suguro, Toru
    Sumida, Takayuki
    MODERN RHEUMATOLOGY, 2008, 18 (01) : 15 - 22
  • [32] Development of alopecia in patients treated with interleukin-17 inhibitors
    Antoury, Layal
    Maloney, Nolan
    Cheng, Kyle
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [33] Interleukin-17 and lupus: enough to be a target? For which patients?
    Robert, M.
    Miossec, P.
    LUPUS, 2020, 29 (01) : 6 - 14
  • [34] The glial response to Interleukin-17
    Jane, Rodgers
    Stephen, Miller
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 228 (1-2) : 26 - 26
  • [35] Interleukin-17 and Its Receptor
    Melanie K. Spriggs
    Journal of Clinical Immunology, 1997, 17 : 366 - 369
  • [36] Interleukin-17 receptor.
    Zhou, LM
    Wang, JX
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 1999, 26 (02) : 101 - 102
  • [37] Interleukin-17 in Inflammatory Myopathies
    Anne Tournadre
    Pierre Miossec
    Current Rheumatology Reports, 2012, 14 : 252 - 256
  • [38] Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis
    Bolt, Janne W.
    van Kuijk, Arno W.
    Teunissen, Marcel B. M.
    van der Coelen, Dennis
    Aarrass, Saida
    Gerlag, Danielle M.
    Tak, Paul P.
    van de Sande, Marleen G.
    Lebre, Maria C.
    van Baarsen, Lisa G. M.
    BIOMEDICINES, 2022, 10 (02)
  • [39] Airway neutrophils and interleukin-17
    Lindén, A
    Hoshino, H
    Laan, M
    EUROPEAN RESPIRATORY JOURNAL, 2000, 15 (05) : 973 - 977
  • [40] Targeting interleukin-17 receptors
    Lee, Wen-Hwa
    Wu, Heng-Hsiung
    Huang, Chun-Kai
    ONCOTARGET, 2015, 6 (21) : 18244 - 18245